Nuveen Select Tax-Free Income Portfolio (NXP) Reaches $14.04 Formed H&S; Ardsley Advisory Partners Raised By $9.80 Million Its Progenics Pharmaceuticals In (PGNX) Stake

Nuveen Select Tax-Free Income Portfolio (NXP) formed H&S with $12.92 target or 8.00% below today’s $14.04 share price. Nuveen Select Tax-Free Income Portfolio (NXP) has $232.65M valuation. The stock increased 0.73% or $0.1 during the last trading session, reaching $14.04. About 54,955 shares traded or 86.05% up from the average. Nuveen Select Tax-Free Income Portfolio (NYSE:NXP) has declined 3.42% since February 7, 2017 and is downtrending. It has underperformed by 20.12% the S&P500.

Ardsley Advisory Partners increased Progenics Pharmaceuticals In (PGNX) stake by 274.51% reported in 2017Q3 SEC filing. Ardsley Advisory Partners acquired 1.40 million shares as Progenics Pharmaceuticals In (PGNX)’s stock declined 34.18%. The Ardsley Advisory Partners holds 1.91 million shares with $14.06M value, up from 510,000 last quarter. Progenics Pharmaceuticals In now has $376.65M valuation. The stock increased 4.89% or $0.25 during the last trading session, reaching $5.36. About 2.08M shares traded or 87.34% up from the average. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has risen 48.41% since February 7, 2017 and is uptrending. It has outperformed by 31.71% the S&P500.

Investors sentiment decreased to 1.11 in 2017 Q3. Its down 0.18, from 1.29 in 2017Q2. It dropped, as 22 investors sold PGNX shares while 34 reduced holdings. 16 funds opened positions while 46 raised stakes. 58.90 million shares or 4.84% less from 61.90 million shares in 2017Q2 were reported. California-based Clarivest Asset Limited Liability Co has invested 0.03% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Manufacturers Life Insurance The has invested 0% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). The California-based Fuller And Thaler Asset Mngmt has invested 0.04% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). State Of Tennessee Treasury Department owns 61,611 shares for 0% of their portfolio. 53,378 are owned by Raymond James. State Of Wisconsin Inv Board has invested 0% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Proshare Limited Co invested 0% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Mufg Americas Hldg invested in 213 shares or 0% of the stock. Natl Bank Of Ny Mellon Corp holds 1.06 million shares. Federated Incorporated Pa reported 0.22% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Sio Capital Llc has invested 0.34% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). 241,276 are held by Cadence Capital Mgmt Ltd Limited Liability Company. First Republic Inv Mngmt holds 0% or 19,277 shares in its portfolio. Cwm Lc holds 0% or 33 shares in its portfolio. Parkside Bancorporation & reported 42 shares.

Among 5 analysts covering Progenics Pharm (NASDAQ:PGNX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Progenics Pharm had 11 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, August 9 by Cantor Fitzgerald. The firm has “Buy” rating by Jefferies given on Tuesday, September 26. The stock of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has “Buy” rating given on Thursday, June 8 by Jefferies. The rating was maintained by Needham on Tuesday, June 20 with “Buy”. The firm earned “Buy” rating on Thursday, October 27 by Aegis Capital. As per Friday, August 7, the company rating was downgraded by Zacks. Brean Capital maintained Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) rating on Thursday, August 6. Brean Capital has “Buy” rating and $14 target. The company was maintained on Friday, August 7 by Needham. The company was upgraded on Monday, February 6 by Needham. The firm earned “Buy” rating on Friday, October 23 by Jefferies.